Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kichul Ko

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
The Journal of Clinical Investigation|May 24, 2022
Specific in situ inflammatory states associate with progression to renal failure in lupus nephritisRebecca Abraham, Madeleine S Durkee, Junting Ai, et al.
Clinical & Developmental Immunology|September 19, 2012
Gene-expression-guided selection of candidate loci and molecular phenotype analyses enhance genetic discovery in systemic lupus erythematosusYelena Koldobskaya, Kichul Ko, Akaash A Kumar, et al.
The Journal of Clinical Investigation|September 4, 2025
Immune cell quantification of in situ inflammation partitions human lupus nephritis into mechanistic subtypesGabriel Casella, Madeleine S Torcasso, Junting Ai, et al.
Nature Communications|July 17, 2021
Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejectionYuta Asano, Joe Daccache, Dharmendra Jain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2016
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial InflammationKichul Ko, Jianing Wang, Stuart Perper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 14, 2014
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritisAndrew J Kinloch, Anthony Chang, Kichul Ko, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
The Journal of Clinical Investigation|May 24, 2022
Specific in situ inflammatory states associate with progression to renal failure in lupus nephritisRebecca Abraham, Madeleine S Durkee, Junting Ai, et al.
Clinical & Developmental Immunology|September 19, 2012
Gene-expression-guided selection of candidate loci and molecular phenotype analyses enhance genetic discovery in systemic lupus erythematosusYelena Koldobskaya, Kichul Ko, Akaash A Kumar, et al.
The Journal of Clinical Investigation|September 4, 2025
Immune cell quantification of in situ inflammation partitions human lupus nephritis into mechanistic subtypesGabriel Casella, Madeleine S Torcasso, Junting Ai, et al.
Nature Communications|July 17, 2021
Innate-like self-reactive B cells infiltrate human renal allografts during transplant rejectionYuta Asano, Joe Daccache, Dharmendra Jain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 10, 2016
Bcl-2 as a Therapeutic Target in Human Tubulointerstitial InflammationKichul Ko, Jianing Wang, Stuart Perper, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 14, 2014
Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritisAndrew J Kinloch, Anthony Chang, Kichul Ko, et al.
The Lancet. Rheumatology|February 1, 2024
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trialEliza F Chakravarty, Tammy Utset, Diane L Kamen, et al.
Pageof 2